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Inﬂammatory bowel diseases (IBDs) are chronic inﬂammatory conditions of the gastrointestinal tract that occur in genetically
susceptible individuals. Crohn’s disease (CD) and ulcerative colitis (UC) are two major types of IBD. In about 20–25% of
patients, disease onset is during childhood and pediatric IBD can be considered the best model for studying immunopathogentic
mechanisms. The fundamentals of IBD pathogenesis are considered a defective innate immunity and bacterial killing with
overaggressiveadaptiveimmuneresponse.Aconditionof“dysbiosis”,withalterationsofthegutmicrobialcomposition,isregarded
as the basis of IBD pathogenesis. The human gastrointestinal (GI) microbial population is a complex, dynamic ecosystem and
consistsofuptoonethousanddiﬀerentbacterialspecies.Inhealthyindividuals,intestinalmicrobiotahaveasymbioticrelationship
with the host organism and carry out important metabolic, “barrier,” and immune functions. Microbial dysbiosis in IBD with lack
ofbeneﬁcialbacteria,togetherwithgeneticpredisposition,isthemostrelevantconditionsinthepathogenesisofthepediatricIBD.
1.Introduction
IBD are chronic inﬂammations of the small bowel and/or
the colon leading to recurrent diarrhea and abdominal pain.
Crohn’s disease (CD) and ulcerative colitis (UC) are the
two main clinicopathological subtypes of IBD. Despite both
being chronic and relapsing inﬂammatory diseases of the
bowel, they can be diﬀerentiated by the location of the
inﬂammation in the gastrointestinal tract and by the nature
of the histological alterations in the intestinal wall. Epidemi-
ology studies suggest that the prevalence of IBD increases in
populations and regions with industrialization [1]. Disease
onset appears typically in young adulthood (between the age
of 25 and 35 years), but in about 20–25% symptoms begin
in pediatric population [2]. Complex interactions between
immune system, enteric commensal bacteria/pathogens, and
host genotype are thought to underlie the development of
IBD [3]. An emerging consensus hypothesis is that intestinal
dysbiosis (microbial imbalance) may be a trigger for IBD. In
children both mucosal immune system and intestinal ﬂora
are still in the developmental stage. Taken together it appears
that pediatric IBDs represent a speciﬁc group of patients
with particular gene defects, phenotypic appearance, drug
responsiveness, and intestinal immunopathology [4].
In this paper, we will discuss the meaning of dysbiosis in
the pathogenesis of pediatric IBD, the weakening of mucosal




The human gut is sterile at birth, but colonization with
numerous bacterial species starts immediately after birth,
thus generating a resident microbiota characterized by
unique bacterial proﬁles and high interindividual and
environmental variation [7]. The adult human microbiota
consist of around 1014 bacterial cells and up to an estimated
1,000 diﬀerent bacterial species [8]. Studies have shown that
the most abundant bacteria phyla found in healthy human
large intestine are Gram-negative Bacteroidetes and Gram-
positive low-GC Firmicutes [9]. Microbiota composition
varies greatly between individuals, with each individual2 International Journal of Inﬂammation
harbouring a unique collection of bacterial species, which
is highly stable over time. The immune regulatory function
of the intestinal microbiota consists of priming the mucosal
immune system and maintenance of intestinal epithelium
homeostasis (Table 1). Studies in germ-free animals have
demonstratedthatthe normalimmune functionofintestinal
mucosa is impaired in the absence of gut microbiota [10].
The “hygiene hypothesis” has been postulated over the years
to justify how fundamental lifestyle has changed from one
with high to one with low microbial exposure and thus
provides an explanation for the higher frequency of IBD
[11]. In this condition, the intestinal immune system has
smaller Peyer’s patches, fewer plasma cells, lower numbers of
CD8 intraepithelial lymphocytes with reduced cytotoxicity,
and impaired antimicrobial peptide and IgA secretion [12].
The intestinal microbiota are vast and quite diverse at
species level. The classiﬁcation of “normal” microbiota is
challenging as each individual possesses a unique collection
of microbial species. Firmicutes and Bacteroidetes are the
two most predominant bacterial phyla inhabitants in the
intestinal tract [13]. The phyla represent the highest taxo-
nomic rank in bacterial classiﬁcation and are composed of
numerous orders, classes, families, and genera with diverse
and broad metabolic, ecological, pathogenic, and symbiotic
properties [14]. The description of phylum proﬁles has
only limited biological relevance for understanding host-
microbe interactions. Evidence suggests that commensal
bacteria play a role in maintaining the integrity of the
intestinal epithelium [15]. Intestinal epithelial cells (IECs)
provide a physical barrier between luminal microbes and
underlyingintestinaltissuestocontroldefenceandtolerance.
IECs express pattern recognition receptors (PRRs) and
can recognize microbial pathogen-associated molecular pat-
terns (PAMPs) and respond to intestinal microbes through
secretion of cytokines and antimicrobial proteins and up-
regulation of surface molecules that mediate intercellular
interactions [16]. Peterson et al. have shown that the
presence of IgA reduces intestinal proinﬂammatory signals
and drives diversity in gut microbiota [17]. A defective
antibacterial, genetically driven barrier allows translocation
and regulation of the microbiota. Commensal bacteria can
have an anti-inﬂammatory eﬀect on the developing immune
system; for example, in the uterus, T-helper type 2 response
is predominant [18]. With gut colonization, a balance
between T-helper types 1 and 2 is established to prevent
the development of allergic food reactions, and to establish
a T-helper type 3 response that provides tolerance to oral
protein antigens. Feeding allows for antigenic stimulation
and bacterial colonization of the gut. This is required for
the development of IgM- and IgA-producing plasma cells
in the intestinal lamina propria [19]. Breast milk provides
passive protection with antibacterial components such as
IgA, lysozyme, and lactoferrin, promotes the development
of commensal ﬂora rich in biﬁdobacteria, and decreases
colonization with potential pathogens. Alterations in the
normal development of the immune system can lead to
chronic disease states. Antibiotic use in the neonatal period
and infancy can interfere with the development of a healthy
commensal ﬂora and may result in subsequent allergic
Table 1: The eﬀect of commensal bacteria on the development of
the immune system.
Inhibits epithelial NF-kB activation and inﬂammatory gene
expression
Activates CD4 cells in Peyer’s patches
Activates CD8 or natural killer cells in intraepithelial leukocyte
spaces
Increases numbers of T and B cells, including CD86-positive
cells
Organizes the special relationships between T, B, and dendritic
c e l l si nt h eP e y e r ’ sp a t c h e s
Increases the numbers of microfold cells
Increases IgA producing B cells
Hypertrophies Peyer’s patches and the development of germinal
centers
disease or inﬂammatory conditions of the intestinal tract
(irritable bowel syndrome and IBD) [20].
In healthy conditions, balanced mechanisms regulate the
host’s immunological tolerance to the continuous stimulus
of resident gut microbiota and their metabolic end products
[21]. Hildebrand et al. have shown that pneumonia prior to
age 5 years, but not later, and consequent and frequent use of
antibiotics were associated with subsequent high risk of CD,
and this may represent either susceptibility or causation. The
results conﬁrm that early exposures to antibiotics inﬂuence
immune function through disruption of bowel colonization
[22].
3. MicrobiotainIBD
The theory is discussed that IBDs represent the consequence
of the loss of immunological tolerance against autologous
ﬂora. Supporting this theory are a limited number of human
studies and a large number of studies in animal models.
It is assumed that the presence of bacteria is essential
for the development of experimental IBD in most models
[23]. Commensal ﬂora appears to exacerbate rather than
directly cause disease [24]. In IBD patients, not only is
the quantity of commensal bacteria reduced but also the
quality of microbiota composition is altered, with reduction
of Firmicutes and Bacteroidetes. As a consequence of this
dysbiosis, the relative abundance of Enterobacteriacae is
increased in IBD patients compared to healthy controls,
although their absolute numbers remained unaltered [25].
These ﬁndings are present also in several studies, which
have observed decreased clostridia concentrations, although
not always accompanied by a decrease in Bacteroides [26].
Macfarlane et al. revealed aberrancies in Biﬁdobacterium
populations in rectal biopsies from IBD patients with
signiﬁcant reductions of the counts [27]. Zhang et al. have
shown that bacterial diversity of lactobacilli is present in
ulcerated tissue compared to nonulcerated tissue in the same
UC individuals [28].
On the other hand, the number of mucosal adherent
bacteria, such as invasive E. coli, or Proteobacteria, such as
Enterobacteriaceae are increased (Table 2). The possibilityInternational Journal of Inﬂammation 3




Enterobacteriacae Clostridium ix and iv groups
Sulphate-reducing bacteria Biﬁdobacteria
that IBDs are a chronic inﬂammatory response directed
against microbial agents has been considered in UC and
CD. Several infectious agents, including Mycobacterium
avium subspecies paratuberculosis (MAP), adherent invasive
E. coli, Yersinia,a n dPseudomonas have been implicated
as triggering agents of CD [29]. Research has excluded
many microorganism including salmonella, campylobacter
jejuni, clostridium diﬃcile, adenoviruses, rotaviruses, and
mycoplasma as primary etiological agents, although some
may be implicated in relapses of CD [30]. One agent that
raised a great deal of controversy is Mycobacterium avium
subspecies paratuberculosis (MAP), which, for many years,
wasconsidered a possible etiologic agent[31].MAPhasbeen
the most enduring infectious candidate to be proposed as a
causative agent of CD although its role in etiology of disease
has often been questioned. Prevalence studies of MAP in
CD patients from many countries worldwide have reported
widely divergent results ranging from 0% to 100%. The
possible role of MAP in CD has also been supported by the
identiﬁcation of MAP DNA using IS900 polymerase chain
reaction (PCR) analysis of media inoculated with peripheral
blood mononuclear cells (PBMCs) from patients [32].
Kirkwood et al. described a comprehensive investigation
into the presence of MAP in intestinal tissue and PBMC
from 142 children presenting with initial symptoms of IBD
prior to treatment. The ﬁnal diagnoses included CD (62
children), UC (26 children), and non-IBD (54 children).
There was evidence of MAP infection in biopsy tissue and/or
PBMC in a total of 45% of children with CD, 35% of
children with UC, and 11% of non-IBD children. The
presence of viable MAP in 4/10 CD patients was conﬁrmed
by isolation of MAP from biopsy specimens. These results
support the hypothesis that MAP infection of intestinal
tissue, perhaps associated with bloodborne spread, may be
implicated especially in the pathogenesis of pediatric CD
[33]. No signiﬁcant correspondence was found between CD-
associated NOD2 polymorphisms, especially in ileal CD,
and MAP infection [34]. Recently, another microorganism,
Escherichia coli, has been under investigation and associated
w i t hi l e a lC D[ 35], but there is no evidence that antibiotic
treatment against coliforms is eﬃcacious in curing IBD
patients. In a number of diﬀerent mouse models of colitis,
it was possible to prevent colitis by raising the mice under
germ-free conditions. The hypothesis was developed that
physiologic intestinal ﬂora is no longer tolerated in IBD.
Since 2001, genom-wide association studies (GWAs) have
revealed more than 30 genes that are associated with IBD
[36]. Among the identiﬁed targets are genes that play an
important role for immunological cell-cell interactions and
signalling, such as tumor necrosis factor (TNF), TNF-
receptor 1 (TNFR1), the interleukin-23 receptor (IL23R)
[37], or interleukin-12p40 (IL12B). More importantly, there
are genes involved in the immune response to bacteria, such
as nucleotide oligomerization domain 2 (NOD2) and the
toll-like receptor 4 (TLR4), as well as the autophagy genes
autophagy-related like 1 (ATG16L1) and immunity-related
GTPasefamilyM(IRGM)[38].ThevariantsofATG16L1and
IRGM autophagy genes cause a defective capacity to process
cell degradation products as well as bacteria and to eliminate
proinﬂammatory stimuli [39]. Three mutually exclusive
theories have been proposed concerning the implication of
bacteria in pathogenesis of IBD, such as an involvement
of persistent pathogen, an abnormally permeable mucosal
barrier leading to excessive bacterial translocation and a
breakdown in the balance between putative “protective” as
against “harmful” intestinal bacteria which can promote
inﬂammation. Bacteria colonizing the gut mucosa have
the ability to strongly adhere to intestinal epithelial cells
(IECs), to invade IECs by a mechanism involving actin
polymerisation and microtubule recruitment and to induce
granuloma formation in vitro [40]. Based on the pathogenic
group, this type of E. coli was deﬁned and named AIEC for
adherent-invasive E. coli (AIEC). AIEC strains were found
to be highly associated with ileal mucosa in CD patients,
suggesting that there are speciﬁc alterations to the ileal
epithelial cells in patients with CD that allow AIEC adhesion.
The receptor involved in AIEC colonization, and abnormally
expressed on ileal mucosa in 35% of CD patients, was
characterized as being the carcinoembryonic antigen-related
cell adhesion molecule (CECAM6). In pediatric population,
genetics plays an even greater role in disease onset and
susceptibility. Itdoes appear,however,thattheNOD2geneis
similarlypresentin30%–35%ofbothadultandpediatricCD
patients. Although the true pathogenic role of NOD2 in CD
remains unknown, it is an important gene involved in innate
immunity which lends support to the notion that genetically
determined defects in innate, and likely adaptive immunity,
alter the way of interaction of mucosal immune system with
resident bacterial ﬂora [41]. This dysregulated interaction
leads to the adaptive immune response, responsible for
the chronic inﬂammatory lesions, and is more evident in
pediatric-age-onset IBD [42].
4. Dysbiosis in IBD: Causeor Effect of the
Mucosal Inﬂammation?
In IBD, dysbiosis could be a key factor in the immunopatho-
genesis of IBD by disrupting the host immune defences
against commensal ﬂora microbes at the mucosal border
[43]. Increased paracellular intestinal mucosal barrier has
long been recognized in IBD with abnormalities in both
its structural integrity and mucus barrier functions [44].
Sewell et al. have hypotized that the penetration of gut
luminal contents into the altered bowel wall impaired
clearance of this material by the innate immune response
and propagation of a secondary inﬂammatory reaction by
the adaptive immune system [45]. Bacterial clearance is4 International Journal of Inﬂammation
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Figure 1: Pathogenesis of IBD: host response and loss of tolerance in intestine.
also altered in IBD, and an interaction between NOD2
and the autophagy system has been elucidated. Frank et
al. performed a genotype-phenotype correlation and gene-
environment interaction study of IBD patients. The results
show that disease phenotype NOD2 composite genotype
(Leu1007fs, R702W, G908R alleles) and ATG16L1 genotype
(T300A allele) were signiﬁcantly associated with shifts in
microbial compositions with reduced bacterial diversity
[46]. Speciﬁcally, members of the Lachnospiraceae family
(Firmicutes phylum) and Bacteroidales (bacterial order)
weredepletedinasubsetofIBDsamples,withaconcomitant
increase in 16S rRNA sequences of Proteobacteria and
Actinobacteria [47]. As a consequence of this dysbiosis, the
relative abundance of Enterobacteriaceae was increased in
IBD patients compared to healthy controls, although their
absolute numbers remained unaltered. More importantly,
this study conﬁrmed that Faecalibacterium prausnitzii,a
member of the Lachnospiraceae family (clostridial cluster IV
and IXa), was reduced in the mucosa of IBD patients [48].
This abnormal microbiota composition shifts complex
interactions that occur between microbes and host and
its metabolic, trophic, and protective functions, such as
immunomodulatory stimulation, strengthening epithelial
barrier integrity [49]. In particular, Clostridium and Bac-
teroides species reduction cause reduction of butyrate and
short-chain fatty acid production. F. prausnitzii have anti-
inﬂammatory and anticolitic properties. Overgrowth of a
class of microorganisms referred to as sulphate-reducing
bacteria (SRB), observed in UC patients, produces sub-
stances which are toxic to colonocytes and blocks protective
mechanisms in intestinal mucosa [50]. Numerous studies
have analysed microbial compositions in individuals with
IBD compared to healthy controls analyzing stool samples,
but it is well accepted that microbial populations from stool
diﬀer from those associated with the mucosa [51–54].
In recent months, however, researchers have been work-
ing to characterize the gut microbiota also in pediatric IBD.
Richness, evenness, and biodiversity of the gut microbiome
were remarkably reduced in 27 children with severe UC
compared with healthy controls, and this could include the
lack of response to steroid therapy [55].
Darfeuille-Michaud et al. showed that in patients with
IBD there was abnormal colonization of the ileal mucosa
by AIEC bacteria that induced the release of high amounts
of TNFα without leading to host cell apoptosis and with
potential ability to induce persistent intestinal inﬂammation
[56]. Some years later, the presence of adhesive invasive
bacterial strains was conﬁrmed in a pediatric population
with IBD, in inﬂamed intestinal tissue [57].
It is possible to suggest that microbiota and micro-
biome are diﬀerent in diﬀerent sites of inﬂamed or non-
inﬂamed gut with loss of tolerance and defective in the
production or function of antibacterial peptides, such as
defensins by the Paneth cells. There is some evidence
that alpha-defensin production is reduced in ileal CD
[58] and that, in colonic CD, there is reduced mucosal
antimicrobial activity with consistently low antibacterial
peptide expression [59]. This quantitative and/or qualitative
alteration leads to lower levels of defensins in the numbers
and type of intestinal microbiota composition and could
promote intestinal inﬂammation. These alterations cause
loss of tolerance to commensal ﬂora and to ampliﬁcation
and maintenance of inﬂammatory response to intestinal
pathogens (Figure 1). In trying to establish a pathogenic role
of dysbiosis in IBD, microbial imbalance triggers a range of
mechanisms with reduced intraluminal levels of butyrate,
with downregulation of epithelial tight junction protein
expression and increased epithelial permeability [50]. Killing
of bacteria reaching the lamina propria, through the “leaky”
epithelium, is also impaired by a genetically predisposed
defective phagocytosis by macrophages. Ineﬀective bacterial
clearance leads to excessive TLR stimulation, secretion of
proinﬂammatory cytokines, and activation of innate and
T-cell mediated immune responses. In summary, defective
killing of phagocytosed organisms, decreased secretion of
antimicrobial peptides, increased mucosal permeability, orInternational Journal of Inﬂammation 5
defective excretion of xenobiotic materials could result in
an overwhelming stimulation of adaptive immune responses
and loss of immunologic tolerance to commensal bacterial
antigens [60]. This disrupted mechanism of tolerance in
epithelial cells may recognize dysbiosis as a primum movens.
Despite these observations, it is not clear if gut microbial
dysbiosisisacauseoraconsequenceofinﬂammatorydisease
[61] as these studies diﬀer in distinct source of microbes and
analytical methods.
5. Conclusions andPerspectives
There have been new ﬁndings in identifying the pathogen-
esis of IBD over the last year, but environment, genetic
makeup, commensal ﬂora, and immune response can be
considered the key factors. Dysbiosis can be considered an
important pathogenetic factor with advancement growth of
invasive pathogenic bacteria. It can also facilitate bacterial
translocation through the intestinal mucosa barrier to the
mesenteric lymph nodes. Analysis of the microbiota of
C Da n dU Ch a ss of a rr e s u l t e di nd i v e r g i n gv i e w so ft h e
importance of the particular bacteria in pathogenesis of IBD.
Not only is the quantity of commensal bacteria in the IBD
intestine reduced but also the quality and diversity of the
commensal composition are altered. On the other hand, the
numberofmucosaladherentbacteria,suchasinvasiveE.coli,
or Proteobacteria, such as Enterobacteriaceae, is increased,
resulting in the so-called state of “dysbiosis.” This condition
may have a pathogenetic role which is more important in
pediatric IBD, where interaction with genetic predisposition
is more signiﬁcant.
Further studies are needed to better deﬁne the true
composition of the microbiota in patients with IBD and
to understand if dysbiosis is a predisposing condition or a
consequence of chronic intestinal inﬂammation.
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